NEURELIS PROVIDES BUSINESS UPDATE HIGHLIGHTING TRANSFORMATIONAL 2025 RESULTS
2025 Net Revenue of $295-300M, EBITDA margin of 30%+ Expansion of VALTOCO (diazepam nasal spray) Patent Portfolio, Extending Market Exclusivity with multiple issuances through 2032 Accelerated Uptake with VALTOCO FDA Label Expansion Approval Including 2 to 5 years of Age San Diego, CA – January 12, 2026 – Neurelis, Inc., the innovator behind VALTOCO® […]
NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
Collection of eight posters include analyses of data from studies of diazepam nasal spray in treatment of episodes of frequent seizures in people with epilepsy aged 2-65 years San Diego, CA – December 5, 2025 – Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will participate in the American Epilepsy Society […]
NEURELIS TO PARTICIPATE IN SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
Company will be joined by its Ambassadors to engage epilepsy community and share their journeys San Diego, CA – November 10, 2025 – Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will join the epilepsy community at the 13th Annual Sofie’s Journey Epilepsy Awareness Day & Education Expo at Disneyland (EADDL), […]
NEURELIS TO PRESENT STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT SYMPTOMATIC CEREBRAL CAVERNOUS MALFORMATIONS (CCM), AT ANNUAL CCM MEETING
Phase 1 clinical study data on NRL-1049 shows dose-proportional increase in exposure and favorable safety profile San Diego, CA – November 6, 2025 – Neurelis, Inc., today announced it will present at the Alliance to Cure Cavernous Malformation (CCM) 21st International CCM Scientific & Clinical Meeting to be held November 6-7, 2025, in Atlanta, Georgia. […]
NEURELIS TO HIGHLIGHT DATA FROM A STUDY OF DIAZEPAM NASAL SPRAY IN PEDIATRIC PATIENTS AT THE CHILD NEUROLOGY SOCIETY ANNUAL MEETING
Poster presentations provide insights into timing of dosing and seizure termination, as well as interval between episodes of frequent seizures following treatment with diazepam nasal spray San Diego, CA – October 8, 2025 – Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will present two posters at the 54th Child Neurology Society […]
NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5
VALTOCO maintains orphan drug exclusivity for VALTOCO to treat episodes of frequent seizures San Diego, CA – [April, 16, 2025] – Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as “acute repetitive seizures”) that are different from […]
Neurelis will Highlight Analyses of Seizure Treatment with Diazepam Nasal Spray at the American Academy of Neurology Annual Meeting
Presentations include post hoc analyses assessing at home treatment of status epilepticus, acute seizure termination and rapid and early seizure termination, and treatment of prolonged seizures. San Diego, CA – April 7, 2025 – Neurelis, Inc., today announced details of three poster presentations at the American Academy of Neurology (AAN) Annual Meeting to be held […]
Neurelis Presents Studies on Seizure Clusters at the American Epilepsy Society Annual Meeting
San Diego, CA – December 6, 2024 – Neurelis, Inc., today announced details of its presentations at the American Epilepsy Society (AES) Annual Meeting to be held December 6-10 in Los Angeles. The collection of ten posters highlights analyses of immediate-use seizure medication for treatment of seizure clusters. A wide variety of presentations include pharmacokinetics […]
Neurelis to Join Epilepsy Community at 12th Annual Sofie’s Journey Epilepsy Awareness Day and Education Expo at Disneyland® Resort
San Diego, CA – November 18, 2024 – Neurelis, Inc., today announced it will participate in the 12th Annual Sofie’s Journey Epilepsy Awareness Day & Education Expo at Disneyland (EADDL), one of the largest gatherings of people with epilepsy, care partners, and healthcare practitioners. The event was established to help address the unmet need for […]
Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties
San Diego, CA – November 14, 2024 – Neurelis, Inc. (“Company”), today announced a transaction with OrbiMed for the sale of the Company’s rights, royalty interests, and related sales milestone payments on global net sales of neffy® (nasal epinephrine) (the “Neffy Receivables”). Neurelis, through its subsidiary Aegis Therapeutics, LLC (“Aegis”), previously entered into an agreement […]